Current Role:
Michael joined Almac Pharma Services, part of Almac Group in 2010 and is currently the Head of Formulation & Process Development and is responsible for all drug product development activities from Phase 1 through to Phase 3 and technical transfer to commercial production. His department covers development and GMP manufacture of non-sterile solid oral dosage forms.
Experience:
Michael graduated in Pharmacy from Sunderland School of Pharmacy and was awarded his PhD from The University of Nottingham. In 1994, he joined SmithKline Beecham Pharmaceuticals working in Pharmaceutical Development on solid oral dosage formulations. In 2002 he moved to Fournier Laboratories Ireland as the Head of Pharmaceutical Sciences, working on nanoparticulate formulations and combination products. In 2006, he returned to GlaxoSmithKline as Technical Director working on the transfer of development projects in to commercial manufacture, with a particular focus on QbD applications and interactions with US, European and International regulatory agencies.
Joined Almac:
2010
